SCHEMBL6842019

SCHEMBL6842019

COc1ccc(C2=NN(Cc3cccc(NC(=O)c4cccs4)c3)C(=O)SC2)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.64
PDE4A P27815 2/20 0.64
PDE4B Q07343 2/20 0.64
PDE4C Q08493 2/20 0.64
PDE4D Q08499 2/20 0.64
PDE3B Q13370 2/20 0.64
PDE3A Q14432 2/20 0.64
KMT2A Q03164 5/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 2/20 0.47
MEN1 O00255 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 2/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
ACKR3 P25106 3/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6842476 0.92 KMT2A (0.54) METPDE4APDE4BPDE4CPDE4D
SCHEMBL6654747 0.89 PDE4B (0.61) METPDE4APDE4BPDE4CPDE4D
SCHEMBL6686835 0.88 PDE4B (0.65) METPDE4APDE4BPDE4CPDE4D
SCHEMBL7802139 0.87 PDE4B (0.70) METPDE4APDE4BPDE4CPDE4D
SCHEMBL7793051 0.87 PDE4B (0.75) METPDE4APDE4BPDE4CPDE4D
SCHEMBL7800598 0.87 PDE4B (0.70) METPDE4APDE4BPDE4CPDE4D
SCHEMBL6842206 0.87 KMT2A (0.51) METPDE4APDE4BPDE4CPDE4D
SCHEMBL6659738 0.87 PDE4B (0.66) METPDE4APDE4BPDE4CPDE4D
SCHEMBL6656287 0.86 MET (0.65) METPDE4APDE4BPDE4CPDE4D
SCHEMBL7798685 0.85 PDE4B (0.69) METPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B MET 4676/4885PDE4A 1/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.